A number of small-molecule agonists for RORα and REV-ERBα, such as the pharmacological agents SR9009 and GSK4112 for REV-ERBα, have been developed404 and are available for use in cellular and animal experiments, but prospective studies on the impact of stable circadian rhythms on CHD and heart failure are still limited.405,406 When considered collectively, the bulk of current research points to considerable clinical value and therapeutic potential for medications that target RORα and REV-ERBα to treat hypertension and atherosclerosis. This evidence concerns the gene NR1D1 and atherosclerosis.